Glucocorticoid-mediated inhibition of RANTES expression in human T lymphocytes

FEBS Lett. 1996 Dec 2;398(2-3):308-11. doi: 10.1016/s0014-5793(96)01238-0.

Abstract

The chemokine RANTES has been implicated in the pathogenesis of allergic inflammatory diseases including asthma and rhinitis which are frequently treated with glucocorticoids. We observed that dexamethasone dramatically inhibited RANTES mRNA expression dose dependently in anti-CD3 activated Hut-78 T cells and human PBMCs. Inhibition of RANTES expression did not appear to be secondary to IL-2 inhibition and required binding to the intracellular glucocorticoid receptor. The down-regulation of RANTES expression by glucocorticoids in T cells may directly contribute to the efficacy of these agents in suppressing cellular infiltration and to their anti-inflammatory properties.

Publication types

  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Anti-Inflammatory Agents / metabolism
  • Anti-Inflammatory Agents / pharmacology*
  • CD4-Positive T-Lymphocytes / drug effects
  • CD4-Positive T-Lymphocytes / immunology
  • CD4-Positive T-Lymphocytes / metabolism*
  • Cells, Cultured
  • Chemokine CCL5 / biosynthesis*
  • Chemokine CCL5 / genetics
  • Dexamethasone / metabolism
  • Dexamethasone / pharmacology*
  • Down-Regulation
  • Hormone Antagonists / pharmacology
  • Humans
  • Interleukin-2 / pharmacology
  • Lymphocyte Activation
  • Lymphocytes / immunology
  • Lymphocytes / metabolism
  • Mifepristone / analogs & derivatives
  • Mifepristone / pharmacology
  • Muromonab-CD3 / immunology
  • RNA, Messenger / genetics
  • RNA, Messenger / metabolism
  • Receptors, Glucocorticoid / metabolism
  • Tumor Cells, Cultured

Substances

  • Anti-Inflammatory Agents
  • Chemokine CCL5
  • Hormone Antagonists
  • Interleukin-2
  • Muromonab-CD3
  • RNA, Messenger
  • Receptors, Glucocorticoid
  • dexamethasone receptor
  • RU 40555
  • Mifepristone
  • Dexamethasone